title: Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma.
abstract: BACKGROUND
  Although inhaled steroids are used as the first line of therapy in asthmatic patients, symptoms of asthma do not improve completely in some patients.
  
  
  OBJECTIVE
  To investigate the effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, in patients with moderate/severe asthma, when combined with beclomethasone dipropionate (BDP).
  
  
  METHODS
  Protocol 1: After a 2-week observation period, 41 patients with moderate asthma were divided into those receiving BDP at 1,600 microg/day or 800 microg/day + pranlukast (450 mg/day). The effect of treatment was evaluated by measuring AM peak expiratory flow rate, symptom score, frequency of beta2-agonists, and daily variability of peak expiratory flow rate. Protocol 2: 39 patients participated in this study including those with moderate asthma on 800 microg/day BDP (group I), severe asthma on BDP at 1,600 microg/day (group II), and severe asthma on 1,600 microg/day BDP + 5 to 20 mg prednisolone (group III). Patients of all groups were additionally treated with pranlukast.
  
  
  RESULTS
  Protocol 1: Both treatment regimens resulted in improvement in each clinical parameter. There were no significant differences in the effects of two treatment regimens. Protocol 2: Pranlukast was effective in group I and II, but not in group III. In groups I and II, pranlukast tended to be more effective when BDP was introduced within the first year of onset of asthma.
  
  
  CONCLUSIONS
  Pranlukast is effective for patients with moderate asthma and those patients with severe asthma who are not treated with oral steroids. Pranlukast is more effective in patients treated with BDP early after onset.
authors.affiliation: The Second Department of Internal Medicine, Nagasaki University School of Medicine, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Tomari
authors.forename: T
authors.initials: T
authors.lastname: Shimoda
authors.forename: T
authors.initials: T
authors.lastname: Kawano
authors.forename: K
authors.initials: K
authors.lastname: Mitsuta
authors.forename: Y
authors.initials: Y
authors.lastname: Obase
authors.forename: C
authors.initials: C
authors.lastname: Fukushima
authors.forename: H
authors.initials: H
authors.lastname: Matsuse
authors.forename: S
authors.initials: S
authors.lastname: Kohno
mesh_terms: D000280:Administration, Inhalation; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D002867:Chromones / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008565:Membrane Proteins; D010366:Peak Expiratory Flow Rate; D018077:Receptors, Leukotriene; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D002867:Chromones; D020024:Leukotriene Antagonists; D008565:Membrane Proteins; D018077:Receptors, Leukotriene; C412375:cysteinyl leukotriene receptor 2; D001507:Beclomethasone; C083169:leukotriene D4 receptor; C047681:pranlukast